This week, 11 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

BioSpecifics Technologies Corp. (BSTC) improves from a C to a B rating this week. BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The company also gets A’s in sales growth, operating margin growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of BSTC stock.

The rating of Repligen Corporation (RGEN) moves up this week, rising from a C to a B. Repligen Corporation is a biopharmaceutical company that develops therapeutics for radiology and neuropsychiatry. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RGEN stock.

This is a strong week for Sarepta Therapeutics, Inc. (SRPT). The company’s rating climbs to A from the previous week’s B. Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of SRPT stock.

Concert Pharmaceuticals, Inc. (CNCE) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

This week, Mesoblast Limited Sponsored ADR’s (MESO) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MESO stock.

ZIOPHARM Oncology, Inc. (ZIOP) is seeing ratings go up from a C last week to a B this week. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

Argos Therapeutics, Inc. (ARGS) boosts its rating from a C to a B this week. Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ARGS stock.

CareDx, Inc. (CDNA) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

This week, Agenus Inc. (AGEN) pushes up from a C to a B rating. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Anthera Pharmaceuticals, Inc.’s (ANTH) ratings are looking better this week, moving up to a B from last week’s C. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases. For more information, get Portfolio Grader’s complete analysis of ANTH stock.

Synergy Pharmaceuticals, Inc. (SGYP) earns a B this week, jumping up from last week’s grade of C. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.